Amgen Inc (AMGN) has been under significant observation by numerous financial analysts and investment management firms, with reports indicating fluctuating positions, ratings and target price changes. Amidst the variability, the company has reported impressive Q4 results. Significant growth has been observed, largely buoyed by strong sales of top-performing drugs.
Barclays has initiated coverage of Amgen with an equal-weight recommendation. Major firms like
Smead Capital Management Inc., Axxcess Wealth Management LLC, NewEdge Wealth LLC and others have adjusted their positions in the stock. The issuance of
$4 Billion in Senior Notes was successful. Noteworthy, Amgen's strategic advancements did not go unnoticed with its expansion in obesity strategy through a collaboration with
Ro on GLP-1 Therapies, and the
European Commission granting approval for Amgen's UPLIZNA® for generalized myasthenia gravis. Adding to the positive outlook, Amgen is investing over half a billion dollars in a new, state-of-the-art Science and Innovation Center at its U.S. global headquarters, further reinforcing its commitment to innovation. Conversely, some stakeholders have reduced their holdings in AMGN, including
Skandinaviska Enskilda Banken AB,
Zions Bancorporation National Association UT, and
Fifth Third Bancorp.
Amgen AMGN News Analytics from Tue, 02 Sep 2025 07:00:00 GMT to Sat, 21 Feb 2026 14:14:57 GMT -
Rating 7
- Innovation 8
- Information 9
- Rumor 2
